<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of recurrent bleeding from esophageal varices in patients with cirrhosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arun J Sanyal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jasmohan S Bajaj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce A Runyon, MD, FAASLD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H70339949"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with cirrhosis who develop portal hypertension (ie, increased pressure within the portal venous system) are at risk for complications, including bleeding from esophageal varices. Portal hypertension is the result of resistance to portal blood flow, which most often occurs in the liver. Variceal bleeding is a decompensating event with a high risk of rebleeding following initial recovery. Measures to prevent recurrent variceal bleeding such as eradicating esophageal varices and improving liver function are important for reducing the risk of mortality. </p><p>This topic will discuss the prevention of recurrent bleeding from esophageal varices in patients with cirrhosis. Management of other complications of cirrhosis and portal hypertension are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1256.html" rel="external">"Ascites in adults with cirrhosis: Initial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">"Ascites in adults with cirrhosis: Diuretic-resistant ascites"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1248.html" rel="external">"Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2645.html" rel="external">"Portal hypertensive gastropathy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1242.html" rel="external">"Hepatic hydrothorax"</a>.)</p><p></p><p>Risk assessment for and primary prevention of variceal bleeding in patients with cirrhosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis"</a> and  <a class="medical medical_review" href="/z/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.)</p><p>Management of acute bleeding from esophageal varices is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.)</p><p>Technical aspects of endoscopic variceal ligation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1264.html" rel="external">"Endoscopic variceal ligation"</a>.)</p><p>The American Association for the Study of Liver Diseases (AASLD) has issued guidance regarding the management of variceal bleeding that is based upon the available evidence and consensus opinion [<a href="#rid1">1</a>]. The recommendations in this topic are consistent with AASLD guidance. Management of variceal bleeding is also addressed in guidelines or consensus statements from the British Society of Gastroenterology and by an international consensus statement (Baveno VII) [<a href="#rid2">2,3</a>].</p><p class="headingAnchor" id="H2895150409"><span class="h1">DEFINITION OF REBLEEDING</span><span class="headingEndMark"> — </span>The literature contains variations in the terminology used to define variceal rebleeding across studies. As a result, several definitions were agreed upon during a consensus conference and were used to develop practice guidelines [<a href="#rid1">1,2</a>] (see  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Definitions'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding time frame:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute variceal bleeding – The episode of acute bleeding is comprised of the time interval from hospital admission (time zero) to 120 hours (day 5). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variceal rebleeding – Variceal rebleeding describes bleeding that occurs ≥120 hours after the first hemorrhage, provided that hemostasis was initially achieved [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically significant bleeding – Defined by a transfusion requirement of two units of blood or more within 24 hours of time zero together with a systolic blood pressure below 100 mmHg, a postural systolic change of more than 20 mmHg, and/or a pulse rate above 100 beats per minute at time zero [<a href="#rid2">2</a>].</p><p></p><p>Active bleeding is defined by hematemesis, bright red blood in the nasogastric tube, melena, pulse rate &gt;100 beats per minute, decrease in systolic blood pressure by ≥10 mmHg, and/or transfusion requirement to maintain hemoglobin in the target range [<a href="#rid4">4</a>]. Failure to control variceal bleeding has also been defined as an adjusted blood requirement index (ABRI) ≥0.75 [<a href="#rid5">5</a>]. The ABRI is calculated by using the number of units of red blood cells transfused and the change in hematocrit:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1">ABRI  =  number of red blood cells transfused ÷ [(final hematocrit - initial hematocrit) + 0.01]  </p></div></div><p></p><p class="headingAnchor" id="H4272790863"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>Left untreated, patients who recover from the first episode of esophageal variceal bleeding have a high rate of rebleeding (up to 60 percent during the first year) [<a href="#rid1">1,6</a>]. </p><p>Risk factors specifically for rebleeding have not been well-defined, while factors linked to the risk of initial bleeding include the size of varices  (<a class="graphic graphic_picture graphicRef61770" href="/z/d/graphic/61770.html" rel="external">picture 1</a>), appearance of varices (ie, red wale marks)  (<a class="graphic graphic_picture graphicRef50222" href="/z/d/graphic/50222.html" rel="external">picture 2</a>), and the variceal pressure [<a href="#rid7">7</a>]. The development of esophageal varices and risk factors for bleeding are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis"</a>.)</p><p class="headingAnchor" id="H826020797"><span class="h1">INITIAL PREVENTIVE STRATEGY</span></p><p class="headingAnchor" id="H2613304493"><span class="h2">Goals of prevention</span><span class="headingEndMark"> — </span>Goals of prevention for patients who recover from the first episode of esophageal variceal bleeding include:</p><p class="bulletIndent1"><span class="glyph">●</span>Preventing recurrent variceal bleeding</p><p class="bulletIndent1"><span class="glyph">●</span>Improving survival</p><p class="bulletIndent1"><span class="glyph">●</span>Preventing complications (eg, infection, renal failure) (see  <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding", section on 'Complications'</a>)</p><p></p><p class="headingAnchor" id="H859244430"><span class="h2">General measures</span><span class="headingEndMark"> — </span>The following measures apply to patients with cirrhosis who recover from an initial episode of bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimize hemostasis</strong> – Management of hemostatic abnormalities in patients with cirrhosis is discussed separately.(See  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refer for liver transplantation</strong> – We refer patients with a Model for End-stage Liver Disease (MELD) score ≥14 and history of esophageal variceal bleeding for liver transplantation evaluation, because transplantation is effective long-term therapy for variceal bleeding and other complications of portal hypertension. Selecting patients for liver transplantation and the pretransplant evaluation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manage chronic liver disease</strong> – Patients with cirrhosis are evaluated for interventions that will slow or reverse the progression of liver disease (ie, avoiding alcohol) and prevent additional insults to the liver (eg, adjusting medications, immunizing against hepatitis A virus and hepatitis B virus). The general management of patients with cirrhosis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'General management'</a>.)</p><p></p><p class="bulletIndent1">Some patients with chronic hepatitis C virus (HCV) and decompensated cirrhosis may be candidates for antiviral therapy, which is associated with improved survival. Selecting patients with HCV for antiviral therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a>.)</p><p></p><p class="headingAnchor" id="H2125108695"><span class="h2">Specific interventions</span></p><p class="headingAnchor" id="H3116858308"><span class="h3">Indications</span><span class="headingEndMark"> — </span>All patients with cirrhosis who recover from esophageal variceal bleeding and do not have a transjugular intrahepatic portosystemic shunt (TIPS) are at risk for rebleeding and should receive prophylactic intervention. Patients who had TIPS performed during the acute episode of bleeding do not require any further intervention specifically for esophageal varices. The role of TIPS in the management of acute variceal bleeding is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p class="headingAnchor" id="H1539009526"><span class="h3">Selecting a strategy</span><span class="headingEndMark"> — </span>Selecting a preventive strategy for patients with cirrhosis takes into account the efficacy, risks, and adverse effects of the interventions, in addition to the patient characteristics that may limit the use of beta blockers or variceal ligation techniques. Our preferred strategy is endoscopic variceal ligation (EVL) combined with a beta blocker for patients without contraindications to beta blockers. (See <a class="local">'Endoscopic variceal ligation plus beta blocker'</a> below.)</p><p>Some patients may not want to undergo or cannot tolerate a series of upper endoscopies with EVL requiring anesthesia (ie, patients with multiple comorbidities). For such patients, we use a beta blocker alone, if there are no contraindications [<a href="#rid8">8</a>]. (See <a class="local">'Beta blocker alone'</a> below.)</p><p>For patients with contraindications to beta blockers, we use EVL alone. (See <a class="local">'Endoscopic variceal ligation alone'</a> below.) </p><p>We do not initiate beta blockers to prevent recurrent bleeding in patients with any of the following conditions because of the risk of adverse events (eg, decreased cardiac output, increased mortality):</p><p class="bulletIndent1"><span class="glyph">●</span>Hyponatremia (serum sodium concentration &lt;130 mEq/L) (see  <a class="medical medical_review" href="/z/d/html/2326.html" rel="external">"Hyponatremia in patients with cirrhosis", section on 'Discontinue beta blockers and other antihypertensive drugs'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute kidney injury [<a href="#rid9">9</a>] (see  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spontaneous bacterial peritonitis: Beta blocker therapy in patients with spontaneous bacterial peritonitis is associated with higher mortality risk [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/1248.html" rel="external">"Spontaneous bacterial peritonitis in adults: Treatment and prophylaxis", section on 'Discontinue nonselective beta blockers'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diuretic-resistant ascites: Beta blocker therapy in patients with diuretic-resistant ascites is associated with higher mortality risk, and this is discussed separately (see  <a class="medical medical_review" href="/z/d/html/1258.html" rel="external">"Ascites in adults with cirrhosis: Diuretic-resistant ascites", section on 'Discontinuing beta blockers'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of adverse effects with beta blockers: Patients with a prior history of adverse effects related to beta blockers are not candidates for therapy (eg, bronchoconstriction, heart failure, acute kidney injury) (see  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systolic blood pressure &lt;90 mmHg; this threshold is supported by consensus statement only [<a href="#rid1">1</a>]. Some UpToDate contributors for this topic use mean arterial pressure (MAP) &lt;82 mmHg as the threshold for avoiding beta blockers because MAP &lt;82 mmHg (<a class="calc calc_professional" href="/z/d/html/101851.html" rel="external">calculator 1</a>) predicts mortality in patients with cirrhosis and ascites [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H467871781"><span class="h3">Options</span></p><p class="headingAnchor" id="H4062422780"><span class="h4">Endoscopic variceal ligation plus beta blocker</span><span class="headingEndMark"> — </span>The preferred strategy for patients who recover from their first episode of variceal bleeding consists of endoscopic variceal ligation plus a beta blocker because this combination is effective for preventing rebleeding [<a href="#rid12">12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>We perform EVL (also referred to as band ligation or banding) in one to two weeks after hospital discharge, and we repeat EVL every two to four weeks thereafter until the varices are eradicated. (See <a class="local">'Endoscopic variceal ligation alone'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We begin a nonselective beta blocker at a low dose (eg, <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> 20 mg once daily or <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> 20 mg twice daily) on day 5 after the initial bleeding episode (provided that vasoconstricting drugs have been stopped and hemostasis has been achieved) for patients with cirrhosis who do not have a contraindication to beta blockers. (See <a class="local">'Beta blocker alone'</a> below and <a class="local">'Selecting a strategy'</a> above.) </p><p></p><p>Combining endoscopic ligation with a pharmacologic intervention containing a beta blocker results in lower rebleeding risk compared with either strategy alone [<a href="#rid12">12,13</a>]. In a meta-analysis of eight trials including 905 patients with a history of variceal bleeding, EVL plus a beta blocker (with or without <a class="drug drug_general" data-topicid="8581" href="/z/d/drug information/8581.html" rel="external">isosorbide mononitrate</a>) resulted in greater risk reduction for rebleeding compared with EVL alone (risk ratio [RR] 0.65, 95% CI 0.45-0.93) or pharmacologic intervention alone (RR 0.61, 95% CI 0.44-0.86) [<a href="#rid13">13</a>]. However, combining endoscopic and pharmacologic interventions did not significantly lower mortality risk compared with either approach alone. These data also support evaluating patients who do not tolerate beta blockers for transjugular intrahepatic portosystemic shunt (TIPS) if they are not at increased risk for adverse events (eg, encephalopathy) [<a href="#rid14">14</a>]. (See <a class="local">'Transjugular intrahepatic portosystemic shunt'</a> below.)</p><p class="headingAnchor" id="H3982254022"><span class="h4">Endoscopic variceal ligation alone</span><span class="headingEndMark"> — </span>The goal of EVL is to eradicate esophageal varices, and it is performed in one to two weeks after hospital discharge and repeated every two to four weeks until the varices are no longer visible endoscopically with insufflation of the esophageal lumen [<a href="#rid15">15</a>]. Most patients require between two and four sessions of endoscopic ligation to eradicate esophageal varices. </p><p>During an upper endoscopy, EVL is performed by attaching a device loaded with rubber bands to the tip of the endoscope. A varix is suctioned into the device and then the rubber band is deployed around the base of the varix, which results in occlusion. The technical aspects and complications of EVL are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1264.html" rel="external">"Endoscopic variceal ligation"</a>.)</p><p>The benefits of endoscopic therapy were established by studies of endoscopic sclerotherapy (ES) [<a href="#rid16">16-18</a>]; however, EVL is preferred for treating esophageal varices because EVL results in greater risk reduction for rebleeding and mortality compared with ES [<a href="#rid19">19</a>]. In a meta-analysis of seven trials including 547 patients, patients treated with EVL had lower risk of rebleeding (Odds ratio [OR] 0.52, 95% CI 0.37-0.74) or mortality (OR 0.67, 95% CI 0.46-0.98) compared with sclerotherapy. </p><p class="headingAnchor" id="H532778569"><span class="h4">Beta blocker alone</span><span class="headingEndMark"> — </span>We begin a nonselective beta blocker at low dose (ie, <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> 20 mg once daily) on day 5 after the initial bleeding episode (provided that hemostasis has been achieved and vasoconstricting drugs [ie, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>] have been stopped) for patients with cirrhosis who do not have a contraindication or intolerance to beta blockers. We titrate the beta blocker dose according to the patient’s heart rate (goal resting heart rate is 55 to 60 beats per minute), and continue therapy indefinitely while monitoring for adverse effects (ie, hypotension). </p><p>In general, we use <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> because of once daily dosing and begin with a low dose (ie, 20 mg daily). If nadolol 20 mg daily is started but does not achieve a resting heart rate of 55 to 60 beats per minute in one to two weeks, then the dose is increased to nadolol 40 mg daily, provided that the systolic blood pressure is ≥90 mmHg (or MAP &gt;82 mmHg, if MAP is being used). (See <a class="local">'Selecting a strategy'</a> above.)</p><p>If the goal heart rate has not been achieved in one to two weeks following the first dose increase, then the dose is further increased to 60 mg daily, provided that the systolic blood pressure is ≥90 mmHg (or MAP &gt;82 mmHg, if MAP is being used for monitoring). These steps are repeated until the patient’s heart rate declines to ≤60 beats per minute or the maximum <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> dose is reached (ie, 160 mg daily in patients without ascites or 80 mg daily in patients with ascites) without developing adverse effects (eg, renal insufficiency).</p><p>The duration of beta blocker therapy varies depending on the patient’s disease course, the development of adverse effects, and clinician preference. Some UpToDate contributors for this topic discontinue beta blockers after esophageal varices have been eradicated with EVL. However, other UpToDate contributors for this topic continue beta blockers indefinitely, even after eradicating esophageal varices, unless liver recompensation occurs as in patients with alcohol-associated cirrhosis who abstain or patients with decompensated hepatitis B virus infection who respond to antiviral therapy. In addition, the patient's heart rate and blood pressure are assessed at each follow-up visit.</p><p>Hepatic venous pressure gradient (HVPG) is not routinely measured because it is invasive and more costly compared with noninvasive monitoring. However, measuring HVPG is an alternative for monitoring response to beta blocker if expertise in the technique is available. Patients are also monitored for adverse effects associated with beta blockers including shortness of breath, fatigue, bronchoconstriction, hypotension, and heart failure. (See <a class="local">'Selecting a strategy'</a> above.) </p><p>The goal of prevention with beta blockers is to lower the portal pressure by reducing portal blood flow, which is accomplished by reducing cardiac output and vasoconstricting the splanchnic circulation [<a href="#rid20">20</a>]. Higher portal pressure leads to larger varices that have a higher risk of bleeding [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis", section on 'Predictive factors'</a>.)</p><p>The use of a beta blockers alone reduces the risk of rebleeding and of death due to rebleeding. In a meta-analysis of 19 trials including 1050 patients with variceal bleeding, use of a beta blocker resulted in lower rates of rebleeding (37 versus 58 percent) and of death from rebleeding (9 versus 15 percent) compared with placebo or control group [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2703124503"><span class="h4">Interventions to avoid</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic sclerotherapy</strong> – We do not use endoscopic sclerotherapy for prevention of variceal rebleeding. EVL is preferred in this setting because patients treated with EVL have lower rates rebleeding, mortality, and therapy-related complications (eg, esophageal ulcerations, strictures) compared with sclerotherapy [<a href="#rid2">2</a>]. (See <a class="local">'Endoscopic variceal ligation alone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrates</strong> – We do not use <a class="drug drug_general" data-topicid="8581" href="/z/d/drug information/8581.html" rel="external">isosorbide mononitrate</a> in combination with beta blockers to prevent rebleeding because of the potential for adverse effects including headache, lightheadedness, and hypotension. While adding a nitrate to beta blocker therapy results in lower portal pressure, this potential benefit is not offset by the higher risk of adverse effects and the lack of improved efficacy [<a href="#rid23">23</a>]. In a meta-analysis of five trials including 459 patients, the risk of rebleeding or mortality was not significantly lower for patients given a beta blocker plus isosorbide mononitrate compared with beta blocker alone. </p><p></p><p class="headingAnchor" id="H70340034"><span class="h1">OPTIONS IF INITIAL STRATEGY FAILS</span></p><p class="headingAnchor" id="H3417423757"><span class="h2">Transjugular intrahepatic portosystemic shunt</span></p><p class="headingAnchor" id="H1487205604"><span class="h3">Strategy for long-term hemostasis</span><span class="headingEndMark"> — </span>Transjugular intrahepatic portosystemic shunt (TIPS) with a covered stent is the preferred strategy for patients who recover from an initial bleeding episode but who then develop recurrent bleeding despite endoscopic variceal ligation and/or beta blocker therapy [<a href="#rid3">3</a>]. We define a failed response to endoscopic variceal ligation (EVL) as recurrent variceal bleeding despite at least one endoscopic treatment session, performed by an endoscopist who is experienced in EVL. In addition, some UpToDate contributors for this topic may perform TIPS for patients without encephalopathy and without severe hepatic dysfunction (ie, MELD &lt;18) who cannot tolerate or have complications from beta blockers or EVL rather than using either intervention alone. (See  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.)</p><p>When a patient with a history of varices presents with a second episode of bleeding, endoscopy is usually performed prior to TIPS to confirm the source of bleeding and exclude other causes (ie, peptic ulcer disease). General management of patients with upper gastrointestinal bleeding from esophageal varices or other sources is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a>.)</p><p>TIPS placement results in cessation of variceal bleeding and also serves to prevent further bleeding. TIPS is used to create a low resistance channel between the hepatic vein and the portal vein using angiographic techniques  (<a class="graphic graphic_figure graphicRef72311" href="/z/d/graphic/72311.html" rel="external">figure 1</a>). The stent functions in a manner similar to a surgically-created portacaval shunt but without the risks associated with major abdominal surgery. (See <a class="local">'Other options'</a> below.)</p><p>Some patients are not candidates for TIPS, and contraindications to TIPS placement (eg, heart failure, sepsis) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p>TIPS placement using a covered stent reduces the risk of rebleeding compared with endoscopic and pharmacologic strategies [<a href="#rid24">24-27</a>]. In a trial of 72 patients with either esophageal or gastric variceal bleeding followed for a median of 23 months, patients with TIPS had a lower rebleeding rate compared with patients treated with endoscopic intervention plus a beta blocker (0 versus 29 percent) [<a href="#rid25">25</a>]. A prior meta-analysis of 11 trials that utilized uncovered stents also demonstrated lower rebleeding rates in patients with TIPS compared with patients receiving endoscopic intervention [<a href="#rid26">26</a>]. </p><p>Whether there are selected patients who would benefit from early TIPS placement (ie, within the first 72 hours of the initial bleeding episode) and who are not at increased risk for adverse events (eg, encephalopathy) remains uncertain [<a href="#rid24">24,28-30</a>]. However, in a trial comparing early TIPS placement with EVL plus beta blocker therapy in 63 patients with acute variceal bleeding, early TIPS resulted in lower rates of rebleeding within a median follow-up of 16 months (3 versus 50 percent) [<a href="#rid24">24</a>]. The use of TIPS for patients with acute variceal bleeding is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)", section on 'Indications'</a>.) </p><p class="headingAnchor" id="H2087570151"><span class="h3">Complications</span><span class="headingEndMark"> — </span>Complications associated with TIPS include hepatic encephalopathy or stent stenosis, which can lead to recurrence of portal hypertension and variceal bleeding. With the advent of polytetrafluoroethylene-covered stents, the risk of TIPS stenosis has declined substantially, but hepatic encephalopathy remains a concern [<a href="#rid31">31,32</a>]. In a trial of 72 patients with variceal bleeding, patients treated with TIPS initially had higher rates of encephalopathy compared with those treated with pharmacologic and endoscopic therapy (35 versus 14 percent); however, after one year, the encephalopathy rates were not significantly different between the groups (38 versus 23 percent) [<a href="#rid25">25</a>]. </p><p>Monitoring for and management of stent stenosis and other complications related to TIPS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">"Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"</a>.)</p><p class="headingAnchor" id="H2366253423"><span class="h2">Liver transplantation</span><span class="headingEndMark"> — </span>Liver transplantation provides successful long-term management of variceal bleeding and other complications of portal hypertension. The value of transplantation as a preventive intervention is limited by the frequently long waiting period before a donor liver is available. Selecting patients for liver transplantation evaluation on the basis of MELD score and complications of portal hypertension is discussed separately. (See <a class="local">'General measures'</a> above and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p class="headingAnchor" id="H70340046"><span class="h2">Other options</span><span class="headingEndMark"> — </span>Historically, surgical creation of a shunt (eg, distal splenorenal shunt, portacaval shunt) was performed to control bleeding and prevent recurrent hemorrhage if other methods failed [<a href="#rid33">33</a>]. However, TIPS placement has become the preferred intervention in this setting because covered stents have favorable long-term patency rates and the risks and morbidity associated with major abdominal surgery are avoided. (See <a class="local">'Transjugular intrahepatic portosystemic shunt'</a> above and  <a class="medical medical_review" href="/z/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Surgery'</a>.)</p><p class="headingAnchor" id="H3159018509"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115541.html" rel="external">"Society guideline links: Cirrhosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114134.html" rel="external">"Society guideline links: Gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H325744997"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17197.html" rel="external">"Patient education: Esophageal varices (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4581.html" rel="external">"Patient education: Esophageal varices (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H70340076"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of prevention</strong> – For patients with cirrhosis who recover from an initial episode of esophageal variceal bleeding, the goals of a preventive strategy are (see <a class="local">'Goals of prevention'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preventing recurrent variceal bleeding</p><p class="bulletIndent2"><span class="glyph">•</span>Improving survival</p><p class="bulletIndent2"><span class="glyph">•</span>Preventing complications (eg, infection, renal failure)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – For patients with cirrhosis who recover from an initial episode of esophageal variceal bleeding, general measures include (see <a class="local">'General measures'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Referral for liver transplantation</strong> – Patients with a MELD score ≥14 and history of esophageal variceal bleeding are referred for liver transplantation evaluation, because transplantation is effective long-term therapy for variceal bleeding and other complications of portal hypertension (see  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of chronic liver disease</strong> – Patients are evaluated for interventions that will slow or reverse progression of liver disease and prevent further injury to the liver (see  <a class="medical medical_review" href="/z/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'General management'</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific interventions </strong>– For patients with cirrhosis who have recovered from an episode of esophageal variceal bleeding, we recommend endoscopic variceal ligation to prevent rebleeding rather than endoscopic sclerotherapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We perform endoscopic variceal ligation in one to two weeks after hospital discharge and every two to four weeks thereafter until varices are eradicated. (See <a class="local">'Endoscopic variceal ligation alone'</a> above.)</p><p></p><p class="bulletIndent1">For patients with cirrhosis who have recovered from an episode of variceal bleeding, we suggest therapy with a beta blocker rather than no pharmacologic intervention (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). A nonselective beta blocker (eg, <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> 20 mg once daily) is started on day 5 after the initial episode of bleeding, provided that vasoconstricting agents have been discontinued, hemostasis has been achieved, and there are no contraindications to beta blocker use. The duration of beta blocker therapy varies depending on the patient’s disease course, the development of adverse effects, and clinician preference. (See <a class="local">'Beta blocker alone'</a> above.) </p><p></p><p class="bulletIndent1">For patients who have a contraindication to or cannot tolerate beta blockers, we use endoscopic variceal ligation alone to prevent recurrent variceal bleeding. (See <a class="local">'Selecting a strategy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who do not respond to initial preventive strategies</strong> – For patients with cirrhosis who initially recover from variceal bleeding but who then develop recurrent bleeding despite endoscopic variceal ligation (EVL) and/or beta blocker, transjugular intrahepatic portosystemic shunt (TIPS) placement with a covered stent is the preferred strategy for long-term hemostasis, provided that there are no contraindications to TIPS placement. We define a failed response to EVL as recurrent variceal bleeding despite at least one session of endoscopic treatment. (See <a class="local">'Transjugular intrahepatic portosystemic shunt'</a> above.)</p><p></p><p class="bulletIndent1">Contraindications to TIPS placement and monitoring for TIPS-related complications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1251.html" rel="external">"Transjugular intrahepatic portosystemic shunts: Postprocedure care and complications"</a> and  <a class="medical medical_review" href="/z/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p></p><p class="bulletIndent1">Liver transplantation provides successful long-term management of variceal bleeding for patients with cirrhosis; however, its value is limited by the frequently long waiting period before a donor liver is available. Selecting patients for liver transplantation and the pretransplant evaluation are discussed separately. (See <a class="local">'General measures'</a> above and  <a class="medical medical_review" href="/z/d/html/4585.html" rel="external">"Liver transplantation in adults: Patient selection and pretransplantation evaluation"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017; 65:310.</a></li><li><a class="nounderline abstract_t">Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015; 64:1680.</a></li><li><a class="nounderline abstract_t">de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022; 76:959.</a></li><li><a class="nounderline abstract_t">de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743.</a></li><li><a class="nounderline abstract_t">de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43:167.</a></li><li><a class="nounderline abstract_t">Garcia-Tsao G, Bosch J. Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol 2015; 13:2109.</a></li><li><a class="nounderline abstract_t">Zhao JR, Wang GC, Hu JH, Zhang CQ. Risk factors for early rebleeding and mortality in acute variceal hemorrhage. World J Gastroenterol 2014; 20:17941.</a></li><li><a class="nounderline abstract_t">Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362:823.</a></li><li><a class="nounderline abstract_t">Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439.</a></li><li><a class="nounderline abstract_t">Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146:1680.</a></li><li><a class="nounderline abstract_t">Llach J, Ginès P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482.</a></li><li><a class="nounderline abstract_t">Puente A, Hernández-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 2014; 34:823.</a></li><li><a class="nounderline abstract_t">Thiele M, Krag A, Rohde U, Gluud LL. Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 2012; 35:1155.</a></li><li><a class="nounderline abstract_t">Albillos A, Zamora J, Martínez J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology 2017; 66:1219.</a></li><li><a class="nounderline abstract_t">Hwang JH, Shergill AK, Acosta RD, et al. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 2014; 80:221.</a></li><li><a class="nounderline abstract_t">Söderlund C, Ihre T. Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment. Acta Chir Scand 1985; 151:449.</a></li><li><a class="nounderline abstract_t">Copenhagen Esophageal Varices Sclerotherapy Project. Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial. N Engl J Med 1984; 311:1594.</a></li><li><a class="nounderline abstract_t">Westaby D, Macdougall BR, Williams R. Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial. Hepatology 1985; 5:827.</a></li><li><a class="nounderline abstract_t">Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med 1995; 123:280.</a></li><li><a class="nounderline abstract_t">Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012; 61:967.</a></li><li><a class="nounderline abstract_t">Albillos A, Tejedor M. Secondary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 2014; 18:359.</a></li><li><a class="nounderline abstract_t">Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990; 336:153.</a></li><li><a class="nounderline abstract_t">Gluud LL, Langholz E, Krag A. Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices. Aliment Pharmacol Ther 2010; 32:859.</a></li><li><a class="nounderline abstract_t">García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 362:2370.</a></li><li><a class="nounderline abstract_t">Holster IL, Tjwa ET, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology 2016; 63:581.</a></li><li><a class="nounderline abstract_t">Papatheodoridis GV, Goulis J, Leandro G, et al. Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999; 30:612.</a></li><li><a class="nounderline abstract_t">Wang X, Liu G, Wu J, et al. Small-Diameter Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation Plus Propranolol for Variceal Rebleeding in Advanced Cirrhosis. Radiology 2023; 308:e223201.</a></li><li><a class="nounderline abstract_t">Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793.</a></li><li><a class="nounderline abstract_t">Manning C, Elzubeir A, Alam S. The role of pre-emptive Transjugular Intrahepatic Portosystemic Shunt in acute variceal bleeding: a literature review. Ther Adv Chronic Dis 2021; 12:2040622321995771.</a></li><li><a class="nounderline abstract_t">Garcia-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013; 58:45.</a></li><li><a class="nounderline abstract_t">Bureau C, Garcia Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27:742.</a></li><li><a class="nounderline abstract_t">Perarnau JM, Le Gouge A, Nicolas C, et al. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial. J Hepatol 2014; 60:962.</a></li><li><a class="nounderline abstract_t">Simonetti RG, Perricone G, Robbins HL, et al. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis. Cochrane Database Syst Rev 2020; 10:CD000553.</a></li></ol></div><div id="topicVersionRevision">Topic 1252 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27786365" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887380" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35120736" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Baveno VII - Renewing consensus in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26047908" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15925423" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192141" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25548492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk factors for early rebleeding and mortality in acute variceal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200386" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Management of varices and variceal hemorrhage in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15977202" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Circulatory function and hepatorenal syndrome in cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24631577" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nonselectiveβblockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3335320" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24373180" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449261" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28543862" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25034836" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of endoscopy in the management of variceal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2931937" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6390203" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sclerotherapy after first variceal hemorrhage in cirrhosis. A randomized multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2993147" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611595" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234982" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The window hypothesis: haemodynamic and non-haemodynamic effects ofβ-blockers improve survival of patients with cirrhosis during a window in the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24679500" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Secondary prophylaxis for esophageal variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973480" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Meta-analysis of value of propranolol in prevention of variceal haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20839387" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573925" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early use of TIPS in patients with cirrhosis and variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26517576" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy +β-blocker for prevention of variceal rebleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462365" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37606572" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Small-Diameter Transjugular Intrahepatic Portosystemic Shunt versus Endoscopic Variceal Ligation Plus Propranolol for Variceal Rebleeding in Advanced Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382120" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33747427" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of pre-emptive Transjugular Intrahepatic Portosystemic Shunt in acute variceal bleeding: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22940408" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617116" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24480619" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33089892" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
